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The Aurora-A kinase gene is amplified in a subset of human tumors and in radiation-induced lympho-
mas from p53 heterozygous mice. Normal tissues from p53/mice have increased Aurora-A protein
levels, but lymphomas from these mice exhibit heterozygous deletions of Aurora-A and/or reduced
protein expression. A similar correlation between low p53 levels and Aurora-A gene deletions and ex-
pression is found in human breast cancer cell lines. In vitro studies using mouse embryo fibroblasts
demonstrate that inhibition of Aurora-A can have either positive or negative effects on cell growth as
a function of p53 status. These data have implications for the design of approaches to targeted can-
cer therapy involving the crosstalk between Aurora-A kinase and p53 pathways.INTRODUCTION
Recent successes in the development of ‘‘targeted’’
therapeutic drugs such as the BCR-ABL kinase inhibitor
Gleevec (Druker, 2004) and the EGFR inhibitors Iressa
and Tarceva (Paez et al., 2004; Lynch et al., 2004) have
stimulated interest in the extension of these approaches
to other cancer targets, in particular other members of the
kinase family. One of the challenges that will have to be
faced during development of these approaches is acquisi-
tion of drug resistance by treated tumor cells, either
through additional mutations in the target gene (Pao
et al., 2005; Kobayashi et al., 2005; Sawyers, 2005) or by
rewiring of signaling pathways that allows escape from
the effects of target inhibition. Analyses of signaling in
bacteria, yeast, and mammalian cells have demonstratedCanthe existence of complex networks that can be rapidly re-
wired in response to external stimuli (Almaas et al., 2004;
Wuchty et al., 2003; Luscombe et al., 2004). These com-
plex networks offer many possibilities for tumor cells to
circumvent the negative effects of targeted inhibitors with-
out necessarily mutating the target gene itself. Increased
knowledge of crosstalk between signaling pathways can
therefore help in the design of therapeutic strategies,
as well as in the selection of patients to be entered into
clinical trials.
The Aurora-A kinase gene has attracted a great deal of
attention as a potential therapeutic target because of its
identification as an oncogene (Bischoff et al., 1998). Com-
mon germline polymorphisms in this gene have also been
shown to confer increased risk of development of a num-
ber of tumor types (Ewart-Toland et al., 2003, 2005).SIGNIFICANCE
Inhibitors of the Aurora-A kinase have been developed by several pharmaceutical companies as potential cancer
therapeutics, based on the known oncogenic activities of this gene in induction of genetic instability and cell trans-
formation. The data presented here demonstrate that inhibition of Aurora-A can in fact provide a growth advantage
to cells that have suffered prior loss of p53. In addition, inhibition of Aurora-A may lead to premature loss of wild-
type p53 function. We conclude that there is an important functional interaction in vivo between p53 and Aurora
kinase, and that this network should be taken into account in the design of clinical trials of these agents for cancer
therapy.cer Cell 11, 161–173, February 2007 ª2007 Elsevier Inc. 161
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Interactions between Aurora-A and p53 in CancerAurora-A kinase has been implicated in the control of
chromosome segregation during mitosis and has been
found frequently amplified in many human cancers (Bis-
choff et al., 1998; Sen et al., 1997; Katayama et al., 2003;
Meraldi et al. 2004). Elevated expression of Aurora-A was
also reported to correlate with genomic instability and
clinically aggressive disease (Zhou et al., 1998; Tanaka
et al., 1999). Aurora-A kinase is involved at multiple levels
in interactions with the p53 pathway, suggesting that
these proteins form part of an integrated functional net-
work. Aurora-A interferes with p53 suppressor function
by at least two mechanisms: first, in vitro studies have
shown that Aurora-A kinase phosphorylates p53 at
Ser315, facilitating MDM2-mediated degradation of p53
in cancer cell lines (Katayama et al., 2004); second,
Aurora-A also phosphorylates p53 at Ser215 and inacti-
vates its transcriptional activity (Liu et al., 2004). On the
other hand, p53 interacts with Aurora-A to suppress its on-
cogenic activity in a transactivation-independent manner
(Chen et al., 2002). Taken together, these data suggest
that deregulation of the functional balance between
Aurora-A and p53 might trigger checkpoint abnormalities,
chromosome instability, and carcinogenesis. However,
the in vivo functional relationship between these pathways
in tumor development has not been comprehensively
investigated.
We have used a genetic approach to study the recipro-
cal interactions between Aurora-A kinase and p53 during
development of radiation-induced mouse lymphomas.
Wild-type p53 protein is induced after exposure to g-radi-
ation and is essential for an efficient response to DNA
damage and repair of induced lesions (for review, see
Fei and El-Deiry, 2003). Germline deficiency of p53 has
been reported to lead to increased chromosomal abnor-
malities (Cross et al., 1995; Fukasawa et al., 1996) and
susceptibility to development of a spectrum of tumors,
the most frequent being lymphoma (Donehower et al.,
1992). Tumorigenesis in p53+/ mice can be accelerated
by exposure to a single dose of g radiation (Kemp et al.,
1994). Analysis of genetic instability using microsatellite
imbalance as well as whole-genome comparative geno-
mic hybridization (CGH) arrays demonstrated, in addition
to extreme genetic instability in an important subset of
these tumors, the existence of p53-dependent genetic al-
terations at several loci (Mao et al., 2004, 2005). We have
now applied CGH array analysis to tumors derived from
p53 null mice and show that the latter have, remarkably,
rather stable genomes compared to tumors from equiva-
lent p53 heterozygous mice. Among the loci that clearly
differed between tumors from heterozygous and null
mice was the Aurora-A kinase locus on distal mouse chro-
mosome 2. This locus was found to be frequently gained
or amplified in tumors from p53+/ mice, but showed de-
letions in a substantial proportion of tumors from the
p53/ mice. These results demonstrate the existence of
a complex reciprocal relationship between Aurora-A and
p53 in vivo, by which inhibition of Aurora-A may act posi-
tively or negatively during tumor development in a p53-
dependent manner.162 Cancer Cell 11, 161–173, February 2007 ª2007 Elsevier IncRESULTS
Genetic Signatures in Lymphomas from p53+/
and p53/ Mice
We carried out whole-genome bacterial artificial chromo-
some (BAC) CGH array analysis to compare the patterns
of genomic instability in radiation-induced tumors from
p53+/ and p53/ mice. In an attempt to recognize global
patterns of genetic alterations in these tumors, we carried
out unsupervised cluster analysis of the whole-genome
BAC profiles generated from these tumors (Figure 1A).
For this purpose, the genome was divided into bins of vari-
able size based on the gain/loss frequency of all samples,
and tumors showing gene copy number losses within
a particular bin were denoted in green, while those regions
showing gains were represented in red (Figure 1). Unsu-
pervised cluster analysis showed that, on average, there
were many more genetic changes in tumors from irradi-
ated p53+/ mice than in those from p53/ mice. Detailed
inspection of these patterns identified a large number of
chromosomal changes that were specific to tumors from
mice with at least one functional p53 allele (Figure 1A).
For example, gain of the c-Myc locus and loss of Fbxw7
(Mao et al., 2004) were found only in tumors from p53+/
mice. These results obtained from genome-wide BAC
CGH array analysis were consistent with data obtained
by microsatellite analysis of allelic imbalances in tumors,
which also demonstrated the relative stability of tumors
from mice with complete germline deletions of p53 (Mao
et al., 2004).
We next compared the spectrum of changes in sponta-
neously arising, as opposed to radiation-induced, tumors
from both p53+/ and p53/ mice (Figure 1B). Overall, the
spontaneous tumors derived from p53+/ mice, although
showing less heterogeneity and instability than in the cor-
responding tumors that arose after radiation exposure
(Figure 1A and Mao et al., 2005), had higher levels of
gene copy number gains and losses than equivalent tu-
mors from the p53 null animals (Figure 1B). Tumors from
p53/ mice tended to cluster together, as did those
from p53+/ mice, with a few exceptions (Figure 1B). We
conclude that the difference in genetic instability between
these tumors is an intrinsic consequence of p53 status
and is not simply due to a difference in response to
radiation.
In contrast to the dramatic increase in genetic instability
evident in tumors from irradiated p53+/ mice, irradiation
of p53/ mice at the same dose level did not lead to
any substantial change in genomic instability patterns
(Figure S1; see the Supplemental Data available with this
article online). This is in agreement with reports indicating
that 4 Gy g radiation of p53/ mice at the age of 5 weeks
did not significantly influence tumor latency, while similar
treatment of p53+/ mice dramatically decreased tumor
latency (Figure 1C; Kemp et al., 1994). The reasons for
the apparent immunity to the effects of radiation in cells
devoid of p53 are unclear, especially in view of the exis-
tence of p53-independent checkpoints that can lead to
apoptosis (Frenkel et al., 1999)..
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Interactions between Aurora-A and p53 in CancerFigure 1. Unsupervised Cluster Analysis
of Genetic Changes in Thymic Lympho-
mas from p53+/ Compared to p53/
Mice
p53 status of the mice is denoted by the col-
ored bars.
(A) Comparison of genetic changes in radia-
tion-induced thymic lymphomas from p53+/
and p53/ mice. The locations of the Fbwx7
and c-Myc loci are denoted by arrows.
(B) Comparison of genetic changes in sponta-
neous thymic lymphomas from p53+/ and
p53/ mice.
(C) Lack of effect of radiation in determination
of tumor latency in p53/ mice. The graph
shows the proportion of surviving mice at dif-
ferent time points after birth. There is no statis-
tically significant difference between mice in
both groups (tested by Kaplan-Meier method
using SPSS package). p53+/ mice are very
sensitive to radiation, and a single dose of 4
Gy decreases their average lifespan by about
30 weeks.
The cluster analyses were carried out using
Cluster V3.0 (http://rana.stanford.edu/
software).Cancer Cell 11, 161–173, February 2007 ª2007 Elsevier Inc. 163
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Interactions between Aurora-A and p53 in Cancerp53-Dependent Gene Copy Gains or Losses
at the Aurora-A Locus
The Aurora-A gene is frequently gained or amplified in tu-
mors from a wide variety of human tissues, including the
colon, lung, pancreas, and breast (Sen et al., 1997;
Bischoff et al., 1998; Katayama et al., 2003). In agreement
with these results, mouse lymphomas from p53+/ mice
showed, in over 55% cases, gains on distal chromosome
2 in the region containing Aurora-A (Figure 2A). Detailed
dissection of the amplicon on chromosome 2 in p53+/ tu-
mors showed that there is a complex pattern of amplifica-
tion (Figures 2B–2D), an observation which mimics the sit-
uation seen in several human cancers (Albertson et al.,
2000). One of these regions includes the Aurora-A gene.
In some cases, the BAC containing the Aurora-A gene
(BAC ID RP23-414K7) was the single most highly ampli-
fied sequence in the region (e.g., Figure 2C). To verify
these genetic imbalances we carried out quantitative Taq-
Man analysis using Aurora-A-specific probes which con-
firmed the data found by the BAC CGH array studies
(Figure 2G). Approximately half of the samples had at least
three copies of the gene, while the remainder appeared to
be diploid at this locus. In complete contrast to the situa-
tion seen in tumors from p53+/ mice, similar tumors from
the p53/ animals not only showed no examples of am-
plification or gain, but in fact gene deletions were ob-
served in 35% of the lymphomas (Figure 2A). In some
cases, the deletions were quite specific, involving a mini-
mal region of only 200 kb containing the Aurora-A gene
(e.g., Figure 2E). Seven of 20 tumors from p53 null mice
analyzed by TaqMan quantitation of Aurora-A gene levels
showed heterozygous deletions, having only the equiva-
lent of one copy (Figure 2I). These data, taken together, in-
dicate that Aurora-A can be a target for either amplifica-
tion or deletion, dependent on p53 status.
Correlation of Aurora-A Protein Levels and Gene
Copy Number
The effects of the genetic imbalances at the Aurora-A lo-
cus on protein levels in the tumors analyzed by CGH
were investigated by western blotting of tumor extracts.
The results shown in Figures 2H and 2J demonstrate
that there is a strong correlation between gene copy num-
bers as determined by quantitative TaqMan analysis and
protein levels both in p53+/ and p53/ mouse tumors.
The numbers under Figures 2H and 2J correspond to
the tumor numbers in Figures 2G and 2I, respectively. Tu-
mors from p53+/ mice that have increasedAurora-A gene
copy number have relatively high protein levels (compare
Figures 2G and 2H), whereas those with deletions have,
on average, lower protein levels than p53/ mouse tu-
mors with two copies of the gene (compare Figures 2I
and 2J). Some tumors from p53/ mice that did not
show genetic loss of Aurora-A nevertheless exhibited
low levels of protein (e.g., tumor numbers NR14, NR19,
and NR20 in Figure 2J), suggesting that different mecha-
nisms can lead to downregulation of Aurora-A protein
levels in p53 null tumors.164 Cancer Cell 11, 161–173, February 2007 ª2007 Elsevier InOne consistent observation was that normal thymus tis-
sue from p53/ mice had higher protein levels of Aurora-
A than the equivalent tissue from p53+/ mice (compare
Figure 2H, lanes 1–4, with Figure 2J, lanes 1–4). Similar
observations were made with other tissues, such as
spleen, from the same animals (data not shown). Interest-
ingly, although tumors from p53 heterozygous and null
mice show diametrically opposed genetic alterations
leading to gains or losses at the Aurora-A locus, the pro-
tein levels, overall, lie within a similar range (compare Fig-
ures 2H and 2J). These data suggest that there may be an
optimal level of Aurora-A protein that is compatible with
rapid cell growth as required for tumor progression. While
this level is generally attained in most tumors containing
wild-type p53 by gene copy number gains, tumors that
develop from cells with no functional p53, and conse-
quently higher starting levels of endogenous Aurora-A
protein (Figure 2J), reduce the amount of Aurora-A protein
to ‘‘acceptable’’ levels by mechanisms that commonly in-
volve gene deletion. The data suggest that in rapidly divid-
ing cells, levels of Aurora-A have to be within a specific
window compatible with ordered progression of mitosis.
Cells that are p53 wild-type or null achieve this goal in
very different ways. The data in Figures 2H and 2J also
show however that some tumors, both from p53 heterozy-
gous and null mice (e.g., HR9, NR10, and NR12), have only
very low levels of Aurora-A and presumably have compen-
sated for this loss by upregulating alternative mecha-
nisms, the nature of which remain unclear. In order to ex-
clude the possibility that activating mutations in Aurora-A
might influence the patterns seen, the complete coding re-
gion of Aurora-A was sequenced in a series of 40 tumors
from p53+/ or p53/ mice. This study did not reveal
the presence of any coding sequence alterations that
might influence Aurora-A activity.
Reduced Levels of AURORA-A in a Subset of Human
Breast Cancers
In order to determine whether any evidence for deletion or
reduced expression of Aurora-A can be found in human
cancers, we measured gene copy number of AURORA-
A in a series of breast cancer cell lines by quantitative Taq-
Man analysis using an AURORA-A-specific probe. As
shown in Figure 3A, about 50% of breast cancer cell lines
had increased copy number of the AURORA-A gene, in
agreement with what has been previously reported for
breast tumors (Sen et al., 1997). However, three cell lines
showed the loss of one copy of the Aurora-A gene, similar
to the situation seen in tumors from p53/ mice. All three
tumors showing reduced copy number also had low levels
of AURORA-A protein, as did some tumors with normal
gene copy number (e.g., HCC70, 600MPE, ZR-75-30,
and SUM185PE; Figure 3B). We conclude that some hu-
man breast tumors exhibit reduced gene copy number
and protein levels of Aurora-A, similar to the lymphomas
from p53/ mice. Clearly, these human tumors cannot
have developed from p53/ normal cells, but it is possi-
ble that mutations leading to loss of p53 function occurred
relatively early in the tumorigenesis process, exertingc.
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at the Aurora-A Locus in Tumors
(A) Frequency of somatic gain/loss of Aurora-A
in lymphomas as a function of p53 status.
(B–D) Representative BAC array profiles of
chromosome 2 in tumors from p53+/ mice.
The arrows indicate the position of the
Aurora-A gene, which is frequently gained in
tumors from p53+/ mice.
(E and F) Loss of the Aurora-A gene in tumors
from p53/ mice.
(G) Detection of Aurora-A genetic alterations in
radiation-induced tumors from p53 heterozy-
gous mice (HR) by TaqMan assay.
(H) Detection of Aurora-A protein levels in radi-
ation-induced tumors from p53 heterozygous
mice (HR) by western blotting. The first four
lanes show levels of Aurora-A in normal thymus
from unirradiated p53+/ mice. Tumors in lanes
labeled HR 1–20 correspond to those labeled
HR1–HR20 in (G).
(I) Detection of Aurora-A genetic alterations in
radiation-induced tumors from p53 null mice
(NR) by TaqMan assay.
(J) Detection of Aurora-A protein levels in radi-
ation-induced tumors from p53 null mice (NR)
by western blotting. The first four lanes show
levels of Aurora-A in normal thymus from unir-
radiated p53/ mice. These are consistently
higher than in corresponding p53+/ mice (H).
Tumors in lanes labeled NR 1–20 correspond
to those labeled NR1–NR20 in (I).selective pressure for loss rather than gain of Aurora-A.
The complete coding region of AURORA-A was se-
quenced in all breast cancer lines shown in Figure 3A.CaAs was also observed for the mouse tumors, no mutations
were detected that might influence the conclusions from
these experiments.ncer Cell 11, 161–173, February 2007 ª2007 Elsevier Inc. 165
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Interactions between Aurora-A and p53 in CancerFigure 3. Alteration of Aurora-A Gene Copy Number and Expression in Human Breast Cancer Cell Lines and Primary Tumors
(A) Detection of Aurora-A gene copy number changes in human breast cancer cell lines by TaqMan assay using Aurora-A-specific probes. The names
of the cell lines used are shown below the TaqMan data.
(B) Detection of Aurora-A protein levels in same set of human breast cancer cell lines by western blotting. The order of the cell lines used from left to
right is the same as in (A).
(C) Comparison of Aurora-A RNA levels between p53+VE (on the right, dark bars) and p53VE (on the left, open bars) human breast cancer cell lines.
Aurora-A RNA levels were derived from Affymetrix array data using two separate probes (204092_s_at and 208709_s_at). p53 protein level was de-
termined by western blotting. p53+VE denotes tumors with detectable p53 protein by western blotting, whereas p53VE denotes tumors with no p53
protein. A low Aurora-A RNA level was significantly correlated with a low p53 protein level.
(D) Protein levels of p53 and AURORA-A in human breast cancer cell lines determined by western blotting.
(E) Comparison of quantitated Aurora-A protein level between p53+VE and p53VE human breast cancer cell lines. Low Aurora-A protein level was
significantly correlated with low p53 protein level. The thick line represents the median, whereas thin lines are ranges, i.e., minimum and maximum
number. The box shows 95% confident intervals of median.
(F) Comparison of Aurora-A RNA levels between p53+VE and p53VE human primary breast tumors. Aurora-A RNA levels were derived from Affy-
metrix microarray data. P53 protein levels were determined by immunobiochemical staining. For details, see Experimental Procedures.Correlation between P53 and AURORA-A Expression
in Breast Cancers
Since it has been shown that genetic changes at the
Aurora-A locus in mouse lymphomas were p53 depen-
dent, we examined the relationship between the levels of
P53 and AURORA-A in human breast cancer cell lines166 Cancer Cell 11, 161–173, February 2007 ª2007 Elsevierby Affymetrix microarray analysis and western blotting.
Genome-wide expression array analysis using the Affy-
metrix platform has been carried out on a large panel of
human breast cancer cell lines (Neve et al., 2006). Inspec-
tion of these array data showed that there was a statisti-
cally significant correlation between the RNA levels ofInc.
Cancer Cell
Interactions between Aurora-A and p53 in CancerAURORA-A and protein levels of p53 (Figure 3C). Tumor
cell lines were separated into two groups based on the
presence or absence of p53 detectable by western blot-
ting. The association between p53 protein status and
Aurora-A RNA levels was statistically significant using
two independent probe sets for Aurora-A (p = 0.037 and
p = 0.048; Figure 3C). We also found a significant associ-
ation between AURORA-A and P53 at the protein level.
Western blotting using AURORA-A-specific antibodies
demonstrated a significant correlation between RNA
expression and protein levels (for probe 204092_s_at:
R = 0.72, p < 0.001; for probe 208079_s_at: R = 0.67,
p < 0.001). The data showed that p53-positive tumors,
as defined in the Experimental Procedures, had on aver-
age higher levels of Aurora-A than tumors with low levels
of p53 (p = 0.024; Figures 3D and 3E). Finally, we searched
for further confirmation of these observations in an inde-
pendent set of Affymetrix RNA expression array data on
primary breast cancers (Chin et al., 2006). Although west-
ern blots of these tumors for p53 were not available, there
was a highly significant association between tumors des-
ignated as p53 positive or negative by immunohistochem-
istry and RNA levels of AURORA-A (Figure 3F). In spite of
the complexity of genetic changes in human tumors, as
opposed to the controlled situation investigated in the
mouse, we conclude that levels of p53 and AURORA-A
are significantly correlated in human breast cancer cell
lines and primary tumors.
Aurora-A Downregulation in p53 Heterozygous
and Null MEFs
The opposite behavior of the Aurora-A locus in tumors
from p53+/ and p53/ mice suggested that Aurora-A
may have either positive or negative effects on cell growth
as a function of p53 status. We designed a small interfer-
ing RNA (RNAi) against Aurora-A and generated stable
transfectants in p53+/ and p53/ MEFs to examine the
effects of Aurora-A downregulation on cell proliferation
and apoptosis. The RNAi effectively reduced Aurora-A
protein expression in MEFs (Figure 4A), but had mimimal
effects on cell morphology (Figure S2). Downregulation
of Aurora-A in p53+/ MEFs initially led to a reduction in
cell proliferation in comparison with controls (Figure 4B,
triangle symbols; Figure S3, lower panel). This reduction
in relative growth continued over eight passages in the
continuous presence of the RNAi, at which point the trans-
fected cells entered a phase of rapid growth that clearly
exceeded the growth rate of control cultures (Figure 4B,
triangle symbols; Figure S3, lower panel). Subsequent
analysis of the p53 status of these cells showed that this
transition was tightly linked to the loss of the wild-type
p53 allele (Figure 4C). Prolonged culture of p53+/ MEFs
under normal conditions ultimately leads to loss of the re-
maining p53 allele, but usually after about 25 passages
(Harvey et al., 1993). In contrast, downregulation of
Aurora-A by RNAi transfection leads to acceleration of
this loss to somewhere between passages 5 and 10, sug-
gesting that inhibition of Aurora-A function selects for
complete loss of p53 function. We conclude that downre-Cgulation of Aurora-A using RNAi may stimulate a p53
checkpoint leading to selection for complete loss of the
remaining gene copy.
In contrast to the situation seen with p53+/ MEFs,
downregulation of Aurora-A in p53/ MEFs did not cause
any obvious decrease in cell growth or proliferation but in
fact induced a slightly higher growth rate than in the corre-
sponding control p53/ cells transfected with the empty
vector or random RNAi constructs (Figure 4B, square
symbols; Figure S3, upper panel). The difference between
RNAi-treated cells and controls appeared to be due to
stimulation of growth rather than increased apoptosis,
shown by increased BrdU incorporation in treated com-
pared to control cell populations (p < 0.01) (Figure 4D).
Comparison of numbers of apoptotic cells by Annexin V
staining did not reveal any significant differences between
treated and control cells, indicating that decreased cell
death was not the explanation for the increase in cell num-
ber (Figure S4). Further analysis of FACS profiles of the
treated and untreated cells showed that those expressing
Aurora-A RNAi had a substantially lower proportion of
cells in the G2/M phases of the cell cycle (Figure 4E).
These data suggested that the reduction in Aurora-A pro-
tein levels in the p53 null cells by treatment with RNAi may
serve to relieve a block at the G2/M stage of the cell cycle,
allowing more rapid progression through mitosis.
Downregulation of Aurora-A Partially Rescues
Genomic Instability in p53 Null MEFs
Loss of the p53 tumor suppressor gene is known to result in
genomic instability (Cross et al., 1995; Fukasawa et al.,
1996; Wahlet al., 1997). Although p53 function has been ex-
tensively investigated in the context of the DNA damage re-
sponse checkpoint, the mechanisms underlying genomic
instability in p53/ cells have not been well established.
Recently it has been demonstrated that in the context of
p53 deficiency there is an increase in the number of tetra-
ploid cells, and that these are more likely than diploid cells
toundergo transformation (Fujiwaraetal., 2005).Wecarried
out detailed FACS analysis of MEFs from p53/ mice be-
fore and after treatment with Aurora-A RNAi. The results
demonstrated that the increased aneuploidy seen in p53
null MEFs (Figure 4E, left panel) was significantly decreased
after RNAi-mediated downregulation of Aurora-A at several
different passage levels (Figure 5). These data, taken to-
gether with the observations of increased G2/M phase cells
and high Aurora levels in p53 null cells (Figure 4E), suggest
that increased Aurora levels are a major contributing factor
to the elevated instability and aneuploidy in p53 null fibro-
blasts. This deregulation of mitosis however comes at the
expense of relatively retarded growth, and both aneuploidy
development and growth defects are at least partially allevi-
ated by inhibition of Aurora-A.
DISCUSSION
Control of mitosis is critical for the ordered regulation of
cell division, and aberrant expression of various compo-
nents of the molecular circuitry responsible for this controlancer Cell 11, 161–173, February 2007 ª2007 Elsevier Inc. 167
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Interactions between Aurora-A and p53 in CancerFigure 4. Aurora-A Downregulation by RNAi in p53 Heterozygous and Null MEFs
Two controls for the experiment were pSUPER vector without RNAi or with scrambled RNAi (see Experimental Procedures), both of which gave the
same results.
(A) Aurora-A protein levels are downregulated by RNAi in p53/ MEFs after selection with 2 mg/ml puromycin.
(B) Downregulation of Aurora-A in p53+/ MEFS produces a clear growth disadvantage at early passages, but growth advantage at late passages,
compared with their untransfected counterparts. p53 null MEFs transfected with the same RNAi construct showed similar behavior independently of
the presence of Aurora-A RNAi at early passages, and a clear growth advantage at late passages.
(C) Loss of the remaining p53 allele in p53+/ MEFs treated with Aurora-A RNAi. p53+/ cells in the presence of scrambled (control) RNAi maintain the
normal p53 allele until around passage 25, but p53+/ cells treated with Aurora-A RNAi lose the wild-type p53 allele between passages 5 and 10.168 Cancer Cell 11, 161–173, February 2007 ª2007 Elsevier Inc.
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Interactions between Aurora-A and p53 in Canceris an important contributing factor to neoplasia. Studies of
the mitotic cycle in Drosophila embryos have identified
many of the critical players in this process and have re-
vealed the complexity of the interactions that ensure ac-
curate execution of the entry into and exit from mitosis
(O’Farrell et al., 1989; Glover 1991). The Aurora A and B ki-
nases interact with and phosphorylate a number of pro-
teins involved in mitotic spindle assembly, and conse-
quently the concentrations of these proteins have to be
maintained within specific limits: either over- or underex-
pression leads to chromosome missegregation and aneu-
ploidy (Glover et al., 1995; Meraldi et al. 2004). The conse-
quences of aneuploidy development in normal cells are
growth arrest or cell death, but in tumors this process is
thought to be a major contributor to the neoplastic pheno-
type (Michor et al., 2005; Rajagopalan and Lengauer,
2004). Deregulation of mitotic control can take place in tu-
mors by amplification and/or overexpression of Aurora-A
kinase, but can also be caused by deregulation of other
members of the Aurora family or their interacting proteins
such as Mad2L1 (Hernando et al., 2004; Meraldi et al.,
2004).
The p53 gene has been shown to be involved in control
of genetic stability, and loss of even a single copy of this
gene in the mouse can result in karyotypic instability and
the appearance of abnormal centrosomes and mitotic fig-
ures (Bouffler et al., 1995; Fukasawa et al., 1996). Com-
Figure 5. Downregulation of Aurora-A Partially Rescues
Genomic Instability in p53 Null MEFs
p53 null MEFs grown in the presence or absence of Aurora-A RNAi
were harvested at the passage levels shown and subjected to FACS
analysis of cell cycle profiles. The percentage of aneuploid cells (de-
fined as cells with >2N DNA content) increases with passage level of
both treated and untreated cultures, but the degree of aneuploidy
was significantly reduced by expression of the Aurora-A RNAi (*p <
0.01). Error bars stand for mean ± SD of three different experiments.Cplete loss of p53 recently has been shown to lead to tetra-
ploidy and, subsequently, to development of malignant
aneuploid tumor cells (Fujiwara et al., 2005). Whole-
genome CGH array analysis, however, demonstrates that
tumors from p53 null mice exhibit less instability than cor-
responding tumors from p53+/ mice, in spite of the fact
that the latter have lost the remaining wild-type p53 allele
and are functionally p53 null. We interpret these data to
mean that the timing of p53 loss is a major determinant
of the level of induced genetic instability. The presence
of a functional p53 protein presumably stimulates down-
stream targets in response to radiation exposure, or to
other forms of stress, and the resultant selective pres-
sures lead to deletions or other genomic rearrangements
that circumvent the induced checkpoints. In the complete
absence of functional p53 at the earliest stages of tumor
development, fewer checkpoints are activated and there
are consequently less requirements for gene copy number
gains or losses leading to their inactivation.
In line with the involvement of both Aurora and p53 in
mitotic control, several laboratories have identified func-
tional interactions between these two proteins in cell cul-
ture model systems (Katayama et al., 2003; Liu et al.,
2004). In a wide a variety of human tumors, and in mouse
tumors that arise in mice with wild-type p53 function, the
gene encoding Aurora-A is frequently amplified and asso-
ciated with aneuploidy development (Zhou et al., 1998). In
the present study, we have demonstrated that prior loss of
p53, as in mice carrying nonfunctional p53 alleles (Done-
hower et al., 1992), leads to a rewiring of this interaction.
Complete loss of p53 leads to upregulation of Aurora-A
through reduced expression of the p53-dependent tumor
suppressor gene Fbxw7, which controls Aurora-A at the
protein level (Mao et al., 2004; Perez-Losada et al.,
2005; Fujii et al., 2006). This mechanism may contribute
to the well-documented chromosome abnormalities, in
particular the tetraploidization, seen in p53 null cells. No-
tably, development of tetraploidy is stimulated by overex-
pression of Aurora-A, and this precedes the detection of
centrosome abnormalities in mouse cells (Meraldi et al.,
2002). This interpretation is further supported by the
observation shown in Figure 5 that downregulation of
Aurora-A in p53 null fibroblasts can partially reduce the
level of aneuploidy, while simultaneously allowing more
rapid cell growth.
With the onset of lymphoma development in vivo in p53
null mice, these high Aurora levels may be incompatible
with ordered progression through mitosis, particularly if
additional components of the mitotic apparatus are also
deregulated by genetic or epigenetic events. As a conse-
quence, in a substantial proportion of tumors, levels of(D) Percentage of BrdU-positive cells in p53/ cultures treated with Aurora-A RNAi (right column) compared to controls (left column). Experiments
were carried out with cells at passages 1 and 6. Inhibition of Aurora-A leads to a net increase in the number of proliferating cells. This experiment was
repeated three times and the results are statistically significant (*p < 0.01). Error bars stand for mean ± SD of three different experiments.
(E) FACS profiles of p53/ cells in the presence or absence of Aurora-A RNAi. The same cell populations used for the analyses shown in (D) were
analyzed by flow cytometry. The proportion of cells in the G2/M phases of the cell cycle was substantially reduced, suggesting, when taken together
with the BrdU incorporation assay shown in (D), that inhibition of Aurora-A releases a G2/M checkpoint and stimulates cell cycle progression. Error
bars stand for mean ± SD of three different experiments.ancer Cell 11, 161–173, February 2007 ª2007 Elsevier Inc. 169
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ruption of the Feedback Loop between
Aurora-A and p53 in Mouse Lymphoma-
genesis
In normal cells with wild-type p53 function, Au-
rora-A levels are controlled at least in part by
the Fbxw7 ubiquitin ligase (left upper panel)
(Mao et al., 2004; Fujii et al., 2006). Loss of
p53 in normal thymus leads to downregulation
of Fbxw7 expression and consequent upregu-
lation of Aurora-A at the protein level (right up-
per panel). In transformed cells from p53+/
mice, Aurora-A levels are increased by gene
copy number gains or by loss of Fbxw7 (or
a combination of both, since Fbxw7 also af-
fects other targets). Subsequent loss of p53
in this case presumably does not change Au-
rora-A levels, because of disruption of this
feedback loop. In p53/ normal cells, Au-
rora-A levels are already very high, such that
in some cases, additional events are required
to reduce the protein level to within an accept-
able window. This is accomplished in some
cases, both in mouse and human tumors, by
single copy gene deletions. The range of levels
of Aurora-A seen in tumors from p53+/ and
p53/ mice is quite similar, but the mecha-
nisms that result in these levels can be different
depending on p53 status.Aurora that are compatible with rapid cell growth are re-
stored by deletion, or in some cases by downregulation
by other mechanisms. In this context, Aurora-A is not a tu-
mor suppressor gene in the classical sense but acts as
a rheostat in control of mitosis.
The relationship between p53 status and Aurora-A
levels is likely to be much more complex in human tumors
than in the mouse, as p53 function can be abrogated by
deletions or truncation mutations leading to loss of func-
tion, or by alternative point mutations that introduce dom-
inant-negative or gain-of-function mutations (Soussi and
Lozano, 2005; Vousden and Prives, 2005). In addition,
the relative timing of genetic events involving Aurora-A
and p53 in human tumors is unclear. Nevertheless, we ob-
served a significant correlation between the levels of p53
and Aurora-A both in breast cancer cell lines and in pri-
mary human tumors. As in the mouse studies, we see
examples of tumor cells with single copy losses of the
Aurora-A gene and correspondingly low protein levels.
One possible explanation is that in a subset of human tu-
mors, p53 mutations leading to loss of function occur prior
to amplification or activation of Aurora-A, such that
Aurora-A deletions are required during further progres-
sion, as seen in the mouse models. This explanation is
compatible with the model shown in Figure 6, by which
the normal feedback loop between p53 and Aurora-A
levels is disrupted in tumor cells. However, the temporal
series of events is very difficult to establish from human tu-
mor analysis, and this mechanism, although compatible
with the mouse data, remains unproven.
The observation of opposite consequences of Aurora-A
inhibition in cells with or without functional p53 has impor-170 Cancer Cell 11, 161–173, February 2007 ª2007 Elsevier Inctant implications for the development of cancer therapeu-
tics aimed at inhibition of this kinase. Our data suggest
that pharmacological inhibition of Aurora-A may in some
cases, depending on individual tumor stage and p53 sta-
tus, lead to decreased aneuploidy but increased growth,
or alternatively to complete loss of wild-type p53 activity.
A recent study of progression of breast ductal carcinoma
in situ (DCIS) demonstrated high expression of Aurora-A at
the preinvasive stage, but decreased expression associ-
ated with development of adjacent invasive lesions in
the same patients (Hoque et al., 2003). In the present man-
uscript, we have identified a subset of human breast can-
cers with genetic loss of Aurora-A and low levels of pro-
tein. While it seems likely that small-molecule inhibitors
of these mitotic kinases will be an important addition to
the armory of agents that may be used for cancer therapy,
our data underline the importance of individualized as-
sessment of the genetic status of Aurora family members
and p53 in human cancers before embarking on extensive
clinical trials of these agents. Further studies of the com-
plex networks of interactions between these and other im-
portant cancer signaling hubs (Vogelstein et al., 2000) will
be required to identify the specific combinations of drugs
that will be necessary for successful therapy of malignant
disease.
EXPERIMENTAL PROCEDURES
Tumor Induction and Preparation of DNA
Five-week-old p53+/ and p53/ 129/Sv mice of both sexes were ex-
posed to a single dose of 4 Gy whole-body radiation and observed
daily until moribund, then sacrificed and autopsied. We performed all.
Cancer Cell
Interactions between Aurora-A and p53 in Canceranimal experiments in compliance with UCSF Laboratory Animal
Resource Center (LARC)-approved protocols.
Thymic lymphomas and normal tails were cut, minced in small
pieces, and placed in a microfuge tube containing 0.5 ml lysis buffer
(100 mM Tris$HCl [pH 8.5], 5 mM EDTA, 0.2% SDS, 200 mM NaCl).
Proteinase K was added at a final concentration of 100 mg/ml and
incubated at 55C overnight. The lysate was extracted twice with an
equal volume of phenol:chloroform:isoamyl alcohol (25:24:1, v/v)
(GIBCO-BRL). DNA in the lysate was precipitated by addition of an
equal volume of isopropanol. The DNA precipitates were dissolved in
TE buffer (10 mM Tris$HCl [pH 8.0] and 1 mM EDTA).
Genome-Wide BAC Microarray
Detailed methods are described in Mao et al. (2005). Normal genomic
DNA from mouse strain C57BL/6J was used as the control, and Cot-1
DNA was used for blocking repetitive sequences in BAC clones and
genomic probes. The Cy5:Cy3 ratios were plotted together along indi-
vidual chromosomes. For each mouse tumor sample, two experiments
were done with reversal of the dye labels to remove any ratio artifact.
TaqMan Assay
We designed TaqMan primers and probes using the Primer Express
Oligo Design Software v1.0 (Applied Biosystems, Foster City, CA).
Probes were FAM probes designed specifically for TaqMan (Applied
Biosystems). All primer sets were used to perform amplifications in
triplicate on the ABI 7700 instrument (Applied Biosystems). Reactions
(50 ml) were performed in 13 TaqMan Universal PCR Master Mix (Ap-
plied Biosystems), 1.6 M primer, 0.4 M probe, 12.5 ng DNA. Cycling
parameters were as follows: 95C for 12 min 3 1 cycle (95C for 20
s, 60C for 20 s, 72C for 60 s)3 40 cycles. Copy number is determined
from the PCR cycle number (CT) at which DNAs reach a threshold
amount of fluorescence above background. To normalize for differ-
ences in the amount of total input DNA, amplification at a reference lo-
cus was performed once per plate in triplicate for each individual DNA.
The CT values for each set of triplicates were averaged. The Ct of the
pooled reference was subtracted from the CT for each locus to obtain
the DCT [DCT = CT (locus)  CT (reference)]. DCt values were deter-
mined for locus in tumor samples and a set of six normal genomic
DNAs. The average of the six DCT values [DCT(normal)] measured
from the normal DNAs was calculated once for each locus in this study
and used in the subsequent calculations for all experiments performed
on a single ABI 7700. DDCT = DCt (tumor)  Average DCT (normal).
Number of copies = 2**(DDCT).
RNAi Generation, Transfection, and MEF Growth Determination
MEFs were prepared from 13.5-day-old embryos from p53 wild-type,
heterozygous, and null mice (129/Sv background). All experiments
were performed with MEFs prepared from embryos from at least two
different litters. The genotype of the MEFs was confirmed by PCR-
based analysis of DNA.
MEFs were infected with high-titer retroviral stocks produced by
transient transfection of 293T ecotropic Phoenix cells. After infection
with the pSUPER retrovirus (OligoEngine) allowing the expression of
RNAi molecules, MEFs were selected with 1–2 mg/ml of puromycin in
the culture medium. The oligonucleotide for Aurora-A RNAi is
AACTGTGTCTCCAGGCCTG. Two controls for the experiment were
pSUPER vector without RNAi or with scrambled RNAi: GGAAGC
CAAGCCAAATGGC. The same results were obtained from both
controls.
For growth (proliferation) curve determinations, cells were seeded
into three 100 mm tissue culture plates at 3 3 105 cells per plate in
DMEM (high glucose) supplemented with 10% FBS and penicillin-
streptomycin. Cell numbers were determined every 3 days by Coulter
counter (Beckman Coulter). Accumulative cell numbers were calcu-
lated at each passage. Experiments were repeated at least three
times.CWestern Blotting
Total protein extracts were prepared from tumor MEFs with RIPA lysis
buffer. For western blots, 50 mg of protein extract per lane was electro-
phoresed, transferred to PVDF membranes (Millipore), and incubated
with Aurora-A antibody (BD Transduction Laboratories); as a control,
the same membranes were stripped and immunoblotted again with
anti-b-actin antibody (AC-15, Sigma). The membranes were washed
and treated with rat anti-specie IgG k-chain secondary antibody con-
jugated to horseradish peroxidase (Amersham Pharmacia). The anti-
gen-antibody reactions were visualized by using an enhanced chemi-
luminescence assay (ECL; Amersham Pharmacia).
Immunochemical Techniques and Immunoblot Quantification
Immunoblot analyses were performed using 20 mg cleared cell lysates.
This material was electrophoretically resolved on denaturing sodium
doedecyl sulfate (SDS)-polyacrylamide gels (4%–12%), transferred
to polyvinylidene difluoride membranes (PVDF, Millipore), and probed
with specific antisera using standard techniques. Bound antibodies on
immunoblots were detected by either chemiluminescent (ECL; Pierce)
or infrared imaging (Li-Cor, Odyssey). Images were recorded as TIFF
files for quantitation (see below). Antibodies: Aurora kinase (mouse
monoclonal IAK1, BD Biosciences), p53 (Ab-6, Oncogene).
Protein Quantification
Protein levels were measured by quantifying emitted chemilumines-
cence or infrared radiation recorded from labeled antibodies using
Scion Image (http://www.scioncorp.com/) or Odyssey software
(http://www.licor.com/) (R.M.N. et al., unpublished data). For each
protein, the blots were made for 4 sets of 11 cell lines, each set includ-
ing the same pair (SKBR3 and MCF12A) to permit intensity normaliza-
tion across sets. A basic multiplicative normalization was carried out
by fitting a linear mixed effects model to log intensity values and ad-
justing within each set to equalize the log intensities of the pair of ref-
erence cell lines across the sets.
Detection of Cell Cycle Changes and Aneuploid Cells by FACS
Analysis
Cells were trypsinized, washed with PBS + 1% FBS, fixed with cold
70% ethanol, treated with propidium iodide (10 mg/ml) and ribonucle-
ase A (100 mg/ml), and subjected to cell cycle analysis using FACS Cal-
ibur (Becton Dickinson). Percentage of aneuploid cells was calculated
with ModFit LT cell-cycle analysis software (Verity Software House,
Topsham, ME).
Detection of Apoptosis by Annexin V
The annexin V-FITC apoptosis detection kit was purchased from BD
Biosciences PharMingen. All procedures were carried out according
to the manufacturer’s instructions.
Detection of BrdU Incorporation in DNA-Synthesizing Cells
When growing cells in a tissue culture flask reached 70% confluence,
BrdU was added at a final concentration of 10 mM. After 1 hr incuba-
tion, cells were collected and processed according to the manufac-
turer’s instructions (BD Biosciences). Levels of BrDU incorporation
were analyzed by flow cytometry.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures, six supplemental figures, and microarray data and can be found
with this article online at http://www.cancercell.org/cgi/content/full/
11/2/161/DC1/.
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